321656-72-8

Upstream product

• 56-23-5 tetrachloromethane 
• 875210-73-4 (R)-2-[(4',4'-dimethoxyethyl)aminocarbonyl]amino-2-(4-bromobenzyl)-N-(3,5-dichlorophenyl)-propionamide 
• 397329-86-1 (R){3-[2-(4-Bromophenyl)-1-(3,5-dichlorophenylcarbamoyl)-1-methyl-ethyl]-ureido}-acetic acid ethyl ester 
• 397329-89-4 phosphoric acid 5-(4-bromobenzyl)-7-(3,5-dichlorophenyl)-5-methyl-6-oxo-6,7-dihydro-5H-imidazo[1,2-a]imidazol-3-yl ester diethyl ester 
• 397329-88-3 3-(4-bromobenzyl)-1-(3,5-dichlorophenyl)-3-methyl-1,6-dehydroimidazo[1,2-a]imidazole-2,5-dione 
• 397329-87-2 [4-(4-bromobenzyl)-1-(3,5-dichlorophenyl)-4-methyl-5-oxoimidazolidin-2-ylideneamino]acetic acid ethyl ester 
• 302840-67-1 (2R)-2-amino-3-(4-bromophenyl)-N-(3,5-dichlorophenyl)-2-methyl-propionamide 

Downstream Products

• 321657-06-1 (R)-3-(4-cyanobenzyl)-1-(3,5-dichlorophenyl)-3-methyl-imidazo[1,2-a]-imidazol-2-one 
• 321723-77-7 acetic acid 4-[5-(4-bromo-benzyl)-7-(3,5-dichloro-phenyl)-5-methyl-6-oxo-6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-butyl ester 
• 796872-01-0 (R)-methanesulfonic acid 3-[5-(4-bromobenzyl)-7-(3,5-dichlorophenyl)-5-methyl-6-oxo-6,7-dihydro-5H-imidazo[1,2-α]imidazolyl-3-sulfonyl]propyl ester 
• 321719-80-6 3-(4-bromo-benzyl)-1-(3,5-dichloro-phenyl)-5-(4-hydroxy-butane-1-sulfonyl)-3-methyl-1H-imidazo[1,2-a]imidazol-2-one 
• 321722-24-1 acetic acid 3-[5-(4-bromo-benzyl)-7-(3,5-dichloro-phenyl)-5-methyl-6-oxo-6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-propyl ester 
• 321721-16-8 3-(4-bromo-benzyl)-1-(3,5-dichloro-phenyl)-5-(3-hydroxy-propane-1-sulfonyl)-3-methyl-1H-imidazo[1,2-a]imidazol-2-one 
• 321721-24-8 5-(3-amino-propane-1-sulfonyl)-3-(4-bromo-benzyl)-1-(3,5-dichloro-phenyl)-3-methyl-1H-imidazo[1,2-a]imidazol-2-one 
• 321656-73-9 (R)-3-(4-bromobenzyl)-1-(3,5-dichlorophenyl)-5-iodo-3-methyl-1H-imidazo[1,2-α]imidazol-2-one 

Relevant academic research and scientific papers

A new and practical boronic acid catalyzed intramolecular cyclodehydration of ureas for the synthesis of LFA-1 antagonists

A streamlined and practical approach to 1H-imidazo[1,2-α]imidazol-2- one LFA-1 antagonist (1) that features as the key step a novel intramolecular boronic acid catalyzed cyclocondensation of a urea and an amide is reported.

Synthesis of 6,7-Dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid amides

Disclosed is an improved multi-step process for preparing a compound of Formula I: wherein R1 to R3 are as defined herein. The compounds of formula I inhibit the binding of human intercellular adhesion molecules to the Leukointegrins

Synthesis of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid amides

Disclosed is a multi-step process for preparing a compound of Formula I: wherein R1 to R3 are as defined herein. The compounds of formula I inhibit the binding of human intercellular adhesion molecules to the Leukointegrins. As a res

Development of a scalable process for 1-(3,5-dichlorophenyl)-5-iodo-3- methyl-(4-methylbenzyl)-1H-imidazo[1,2-a]imidazol-2-one: A key intermediate for the synthesis of LFA-1 inhibitors

A safe, robust, chromatography-free and reproducible process for the multi-kilogram synthesis of vinyl iodide 2, a key intermediate for the synthesis of LFA-1 inhibitors, was developed and implemented at the pilot plant. Execution of the above process all